Gain Therapeutics is a clinical-stage biotech developing small molecule drugs for diseases caused by misfolded proteins, with Parkinson's disease as its primary focus. Its lead drug candidate, GT-02287, is designed to bind to and stabilize glucocerebrosidase (GCase), an enzyme that misfolds and loses function in certain forms of Parkinson's disease, triggering a toxic cascade in brain cells. Unlike existing Parkinson's therapies, which only treat symptoms, GT-02287 targets the underlying biology. It is an oral daily pill that crosses the blood-brain barrier, which is a key limitation of competing approaches like enzyme replacement therapy and gene therapy. GT-02287 targets patients both with and without a GBA1 genetic mutation. Beyond Parkinson's, GT-02287 may also apply to Gaucher disease, dementia with Lewy bodies, and Alzheimer's disease. Drug discovery is built around Gain Therapeutics' proprietary computational platform, Magellan, which uses 3D protein structure analysis and AI-driven virtual screening to identify allosteric binding sites on disease-causing proteins — locations distinct from the active site — allowing drugs to restore protein function without blocking it. The core Magellan technology was in-licensed from Minoryx Therapeutics, with royalties owed on future net revenues. GT-02287 completed Phase 1a and is currently in Phase 1b trials, with Phase 2 planned for the second half of 2026. Gain Therapeutics has no approved products or commercial revenue, and funds operations through equity financing. The company's long-term path to value is either independent commercialization or partnering with a larger pharma company through licensing or co-development.